At its meeting on 01 August 2022 the Transparency Council adopted Position No. 68/2022 on the evaluation of the drug Onureg (azacitidine) under the drug programme: “Treatment of patients with acute myeloid leukaemia (ICD-10 C92.0)”.
At its meeting on 01 August 2022 the Transparency Council adopted Position No. 68/2022 on the evaluation of the drug Onureg (azacitidine) under the drug programme: “Treatment of patients with acute myeloid leukaemia (ICD-10 C92.0)”.